Akèy › Kansè ovè › Kalifòni › San Diego
Etid klinik pou Kansè ovè nan San Diego, CA
24 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote San Diego (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- UC San Diego Medical Center - Hillcrest, San Diego
- Sharp Memorial Hospital, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mi lwen
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of San Diego Moores Cancer Center, La Jolla · 11 mi lwen
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891, San Diego
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, San Diego
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- University of California San Diego, La Jolla · 11 mi lwen
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Moores Cancer Center, La Jolla · 11 mi lwen
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ap rekriteFaz 2
- UC San Diego Health - Moores Cancer Center /ID# 277574, La Jolla · 11 mi lwen
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- University of California, San Diego-Moores Cancer Center, La Jolla · 11 mi lwen
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 2
- Scripps Healthscripps Mercy Hospital Prebys Cancer Center, San Diego
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- University of California, San Diego, La Jolla · 11 mi lwen
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ap rekriteFaz 2
- UC San Diego Health, La Jolla · 11 mi lwen
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Scripps Health, San Diego
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mi lwen
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Ap rekriteFaz 3
- UC San Diego Health - Moores Cancer Center, La Jolla · 11 mi lwen
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Kaiser Permanente-San Diego Zion, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- University of California, San Diego; Moores Cancer Center, San Diego
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #101, La Jolla · 11 mi lwen
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ap rekriteFaz 3
- Scripps Clinic, La Jolla · 11 mi lwen
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- UCSD Moores Cancer Center, La Jolla · 11 mi lwen
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Ap rekriteFaz 3
- University of California San Diego Moores Cancer Center, La Jolla · 11 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, La Jolla · 11 mi lwen
A Beta-only IL-2 ImmunoTherapY Study
Ap rekriteFaz 1/2
- Sharp Memorial Hospital, San Diego
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan San Diego
- Kansè Poumon ki pa ti selil48 etid
- Kansè nan tete41 etid
- Kansè (tout kalite)32 etid
- Kansè pwostat31 etid
- Kansè Metastatik30 etid
- Kansè kolorektal25 etid
- Kansè pankreyas24 etid
- Kansè poumon23 etid
- Obèsite23 etid
- Ensifizyans kadyak23 etid
- Depresyon21 etid
- Melanom18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.